<DOC>
	<DOC>NCT00678210</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.</brief_summary>
	<brief_title>Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Have been diagnosed with plaque psoriasis for at least 6 months. Have plaque psoriasis covering at least 15% of their total body. Be a candidate for phototherapy or systemic treatment of psoriasis (either na√Øve or history of previous treatment). Be willing and able to comply with scheduled visits, treatment plan and other study procedures. Currently have nonplaque forms of psoriasis or druginduced psoriasis. Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy. Subject is participating in another trial using an investigational agent or procedure. Women who are pregnant or breastfeeding or considering becoming pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>dose response; PASI 75 response endpoint; subjects with moderate to severe chronic plaque psoriasis</keyword>
</DOC>